An Icelandic scaleup has sparked hopes of a breakthrough in dementia treatment after raising €26.5mn for groundbreaking research. Arctic Therapeutics (ATx) attracted the investment after pioneering a new approach to drug development. Founded in 2015, the company first analyses genomic data with bioinformatics — a blend of computer science and biology. After identifying disease-associated genes and proteins, ATx targets the root causes of a given condition. According to the scaleup, the process cuts the risks, costs, and time involved in developing treatments. The new financing could push the benefits closer towards patients. ATx said the Series A funds will advance…This story continues at The Next Web [...]
AI smart glasses win major funding to support dementia care, though real-world effectiveness and long-term impact remain uncertain despite early promising observations. [...]
In a striking act of self-critique, one of the architects of the transformer technology that powers ChatGPT, Claude, and virtually every major AI system told an audience of industry leaders this week [...]
Researchers at Toshiba Europe have used quantum key distribution (QKD) cryptography to send messages a record 254km using a traditional fibre optic cable network. It’s the first time scientists have [...]
The journey from a laboratory hypothesis to a pharmacy shelf is one of the most grueling marathons in modern industry, typically spanning 10 to 15 years and billions of dollars in investment. Progress [...]